Trials / Completed
CompletedNCT02269319
MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
A Phase 2, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of MRX-I Versus Linezolid in Adult Subjects With Acute Bacterial Skin and Skin Structure Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- MicuRx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRX-I | Oral MRX-I 800mg given twice a day for 10 days |
| DRUG | Linezolid | Oral linezolid 600mg given twice a day for 10 days |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-08-01
- Completion
- 2015-09-01
- First posted
- 2014-10-21
- Last updated
- 2024-11-04
- Results posted
- 2024-11-04
Source: ClinicalTrials.gov record NCT02269319. Inclusion in this directory is not an endorsement.